Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab

US10460831B2 · kind B2 · utility

Assignee

• KONINIKLIJKE PHILIPS N.V. · NL

Inventors

• Vinay Varadan · Dobbs Ferry, US
• Sitharthan Kamalakaran · Pelham, US
• Angel Janevski · New York, US
• Nilanjana Banerjee · Armonk, US
• Nevenka Dimitrova · Pelham Manor, US
• Lyndsay Harris · Chagrin Falls, US

Key dates

• Filing date: Nov 22, 2013
• Grant date: Oct 29, 2019
• Expiry date: Apr 28, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-β signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample (70) of a breast tumor of a patient acquired before initiating (71) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample (72) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-β signaling pathway. Related predictive outcome assessment test development methods are also disclosed.